A First in Human Study for the Versa Device for Tricuspid Regurgitation - Trial NCT06368401
Access comprehensive clinical trial information for NCT06368401 through Pure Global AI's free database. This phase not specified trial is sponsored by Versa Vascular, Inc and is currently Not yet recruiting. The study focuses on Tricuspid Regurgitation. Target enrollment is 10 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Versa Vascular, Inc
Timeline & Enrollment
N/A
Jun 01, 2024
Dec 31, 2025
Primary Outcome
Acute Procedural Success,Incidence of major adverse events (MAE)
Summary
This study is prospective, non-randomized, single-arm,first in human study to evaluate the
 safety and feasibility of the Versa Vascular System for intervention in adults with severe
 tricuspid regurgitation who are not surgical candidates.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06368401
Device Trial